BMO Capital analyst Do Kim reiterated an Outperform rating and $7 price target on Fate Therapeutics (NASDAQ: FATE) saying SITC ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Fate Therapeutics (FATE) Misses Q3 EPS by 2c, Beats on RevenuesNovember 1, 2017 4:05 PM Fate Therapeutics Reports Third Quarter 2017 Financial ResultsNovember 1, 2017 4:02 PM Fate Therapeutics Announces Six Presentations at the 2017 ASH Annual MeetingNovember 1, 2017 9:01 AM